Weekly Analysts’ Ratings Updates for Edwards Lifesciences (EW)

Edwards Lifesciences (NYSE: EW) has recently received a number of price target changes and ratings updates:

• 4/4/2024 – Edwards Lifesciences had its price target raised by analysts at Evercore ISI from $86.00 to $92.00. They now have an “in-line” rating on the stock.
• 4/3/2024 – Edwards Lifesciences had its price target raised by analysts at Citigroup Inc. from $90.00 to $98.00. They now have a “neutral” rating on the stock.
• 3/26/2024 – Edwards Lifesciences was upgraded by analysts at OTR Global from a “mixed” rating to a “positive” rating.
• 3/21/2024 – Edwards Lifesciences had its price target raised by analysts at Morgan Stanley from $95.00 to $103.00. They now have an “overweight” rating on the stock.
• 3/20/2024 – Edwards Lifesciences was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 3/18/2024 – Edwards Lifesciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $93.00 to $100.00. They now have an “outperform” rating on the stock.
• 3/12/2024 – Edwards Lifesciences was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/7/2024 – Edwards Lifesciences was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating.
• 2/13/2024 – Edwards Lifesciences was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Edwards Lifesciences Stock Up 0.8 %

Shares of NYSE:EW traded up $0.71 during trading on Tuesday, reaching $93.05. 2,631,109 shares of the company traded hands, compared to its average volume of 3,969,763. The firm has a fifty day simple moving average of $89.03 and a 200 day simple moving average of $77.18. The firm has a market cap of $56.01 billion, a P/E ratio of 40.46, a price-to-earnings-growth ratio of 4.59 and a beta of 1.05. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the business posted $0.64 EPS. Analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now owns 4,486 shares in the company, valued at approximately $388,801.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 204,004 shares of company stock worth $17,922,954. 1.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Castleview Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter valued at about $25,000. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $28,000. Compass Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $31,000. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $34,000. Finally, O Dell Group LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $34,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.